Specimen record — masthead
About This Site
Medicine Retatrutide is an independent editorial publisher. Not a clinic. Not a pharmacy. Not a prescription service.
What this site is
Medicine Retatrutide is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The 'medicine' in the domain name is editorial positioning — the site occupies the perspective of a pharmacopeia or apothecary's specimen record relative to the research literature. It is not a claim to offer medical services. We are a research digest, not a medical provider.
This site does not have a person named as its author or editor. No real individual's name, credentials, or photograph is claimed on this site. The site is an editorial publication, not a personal practice.
What we document
The retatrutide research record to date: Phase 1b first-in-human pharmacokinetics, Phase 2 obesity and diabetes trials, the MASLD (fatty liver) substudy, and the ongoing Phase 3 TRIUMPH program. Structural pharmacology from cryo-EM work. Pipeline reviews from expert clinical pharmacologists.
We document what was measured, what was found, and what remains open. We do not speculate beyond published data. Investigational status is stated wherever relevant — retatrutide is not approved, and no page on this site implies otherwise.
The editorial angle for this site is pharmacokinetics: the half-life, the structural basis of albumin binding, the dose-escalation rationale, the routes studied. That lens shapes which aspects of the literature receive the deepest treatment.
What we are not
We are not a clinic, a telehealth service, or a pharmacy. We do not offer consultations, diagnoses, prescriptions, or treatment plans. We do not supply or link to vendors of retatrutide or any other compound. We do not provide reconstitution instructions or dosing guidance.
Retatrutide is investigational. The FDA has not approved it. Any gray-market material sold as retatrutide is unregulated and of unverified identity. This site does not facilitate access to that market.
If you are looking for a clinical trial: ClinicalTrials.gov (search 'LY3437943' or 'retatrutide') lists active TRIUMPH trial sites. That is the only legitimate current access route for retatrutide.